ADC Therapeutics (ADCT) Long-Term Investments (2020 - 2024)
ADC Therapeutics (ADCT) posted Long-Term Investments of $260000.0 for Q2 2024, down 72.04% sequentially from $930000.0 in Q1 2024, and down 99.08% YoY from $28.3 million in Q3 2023.
ADC Therapeutics (ADCT) Long-Term Investments (2020 - 2024) Analysis & Trends
ADC Therapeutics has reported Long-Term Investments for 5 years, with the latest figure at $260000.0 in Q2 2024.
- Quarterly Long-Term Investments fell 99.08% year-over-year to $260000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $260000.0 (down 99.08% YoY) and the FY2023 annual result came in at $1.6 million, down 78.37% from the prior year.
- Long-Term Investments fell to $260000.0 in Q2 2024 per ADCT's latest filing, from $930000.0 in the prior quarter.
- Over five years, Long-Term Investments peaked at $47.9 million in Q4 2020 and troughed at $260000.0 in Q2 2024.
- A 5-year average of $27.2 million and a median of $29.5 million in 2023 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2022 and 2024: Long-Term Investments declined 18.25% in 2022, then tumbled 99.08% in 2024.
- Over 5 years, Long-Term Investments stood at $47.9 million in 2020, then tumbled by 63.06% to $17.7 million in 2021, then sank by 56.98% to $7.6 million in 2022, then plunged by 78.37% to $1.6 million in 2023, then tumbled by 84.21% to $260000.0 in 2024.
- According to Business Quant data, Long-Term Investments over the past three periods registered $260000.0, $930000.0, and $1.6 million for Q2 2024, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | ADC Therapeutics | 154.55 Mn | -64.56 Mn | 17.14 Mn | 15.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 260,000.00 |
| Mar 31, 2024 | 930,000.00 |
| Dec 31, 2023 | 1.65 Mn |
| Sep 30, 2023 | 26.99 Mn |
| Jun 30, 2023 | 28.32 Mn |
| Mar 31, 2023 | 29.53 Mn |
| Dec 31, 2022 | 7.61 Mn |
| Sep 30, 2022 | 34.69 Mn |
| Jun 30, 2022 | 36.82 Mn |
| Mar 31, 2022 | 38.73 Mn |
| Dec 31, 2021 | 17.70 Mn |
| Sep 30, 2021 | 44.00 Mn |
| Jun 30, 2021 | 46.21 Mn |
| Mar 31, 2021 | 47.38 Mn |
| Dec 31, 2020 | 47.91 Mn |